Neoleukin

Neoleukin Therapeutics is at the forefront of de novo protein design, utilizing cutting-edge computational methods to create entirely new therapeutic proteins. These proteins are specifically designed to treat a range of immunological disorders, including cancer and autoimmune diseases. The company's lead program, NL-201, is believed to be the first computationally designed de novo protein therapeutic, marking a significant milestone in the field. Neoleukin operates in the biotechnology sector, primarily serving patients with complex immunological conditions. The business model focuses on research and development, with revenue generated through partnerships, collaborations, and potential future product sales. The company is committed to advancing science and improving patient outcomes, supported by a dedicated team and a broad set of programs targeting multiple indications.

Keywords: de novo protein design, computational methods, therapeutic proteins, cancer treatment, autoimmune diseases, biotechnology, NL-201, immunological disorders, research and development, partnerships.